Google.org

Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.

Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve operational efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Diverge Health is a healthcare platform focused on enhancing the capabilities of primary care practices to serve underserved patient populations effectively. The company provides essential infrastructure, including highly trained community health teams, administrative support, and advanced technology. This comprehensive support enables primary care providers to manage local population health more efficiently, ensuring high-quality care delivery. By equipping practitioners with the necessary tools and resources, Diverge Health aims to facilitate improved health outcomes for patients and assist providers in adapting to value-based payment models.

Jacaranda Health is a medical services provider in Kenya, specializing in maternal and child health. It operates clinics in underserved, peri-urban areas, offering high-quality, affordable care, including maternity services, general healthcare, and nursing mentorship. Jacaranda's services are designed to be patient-centered and cost a fifth of what's charged by other private hospitals. Notably, the company has achieved a zero maternal mortality rate, significantly lower than Kenya's national average of 400 per 100,000 births. Additionally, Jacaranda engages in research and innovation to improve its services and develop new tools for low-income women.

Ubie, Inc. is a Tokyo-based company founded in 2017 that specializes in developing artificial intelligence-powered healthcare solutions. Its core offering is an AI-driven symptom checker that generates personalized evaluation reports for patients. Through a brief questionnaire that customizes its inquiries based on factors such as biological sex, age, medical history, and lifestyle choices, the tool aims to assist users in understanding potential causes of their symptoms. In addition to providing patients with detailed reports, Ubie also supplies physicians with patient summaries and predictive diagnoses to enhance clinical decision-making.

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

AccuLine is a digital healthcare company dedicated to preventing heart attacks and saving lives through early detection of coronary artery disease (CAD). The company has developed CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. This innovative platform delivers swift and cost-effective assessments, allowing healthcare providers to identify CAD more effectively and efficiently. By replacing outdated and labor-intensive methods, AccuLine aims to enhance patient outcomes and revolutionize the way heart disease is diagnosed and managed.

Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly those experiencing menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancers, and menstrual problems. Its clinical platform provides personalized treatment protocols crafted by clinicians with expertise in female midlife health. Midi Health utilizes specialized at-home labs, prescription medications, supplements, and lifestyle coaching to support women in managing the challenges they encounter during critical stages of their lives and careers. By focusing on a holistic approach, Midi Health aims to empower women to achieve better health outcomes.

Founded in 2005, Benefits Data Trust (BDT) is a national not-for-profit organization committed to transforming how individuals in need access essential benefits and services.

Oula Health, Inc. is a maternity care provider based in Brooklyn, New York, established in 2019. The company focuses on redesigning maternity care by integrating obstetrics and midwifery to create a personalized and evidence-based experience for expecting families. Oula operates clinics and offers home-based prenatal care services, aiming to set a new standard for pregnancy care that harmonizes modern medical practices with a compassionate approach. Through its innovative model, Oula Health seeks to enhance the overall maternity care experience for its clients.

Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve operational efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights.

Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly those experiencing menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancers, and menstrual problems. Its clinical platform provides personalized treatment protocols crafted by clinicians with expertise in female midlife health. Midi Health utilizes specialized at-home labs, prescription medications, supplements, and lifestyle coaching to support women in managing the challenges they encounter during critical stages of their lives and careers. By focusing on a holistic approach, Midi Health aims to empower women to achieve better health outcomes.

Jacaranda Health is a medical services provider in Kenya, specializing in maternal and child health. It operates clinics in underserved, peri-urban areas, offering high-quality, affordable care, including maternity services, general healthcare, and nursing mentorship. Jacaranda's services are designed to be patient-centered and cost a fifth of what's charged by other private hospitals. Notably, the company has achieved a zero maternal mortality rate, significantly lower than Kenya's national average of 400 per 100,000 births. Additionally, Jacaranda engages in research and innovation to improve its services and develop new tools for low-income women.

MATCH: Music Attuned Technology – Care via eHealth improves the daily lives of dementia patients, their families, and caregivers by harnessing the power of music.

Caraway is a digital healthcare company focused on providing integrated mental, reproductive, and physical healthcare services specifically for college women. Designed with input from students, Caraway delivers a personalized and equitable care solution that addresses the unique needs and concerns of women during a crucial developmental period. The platform emphasizes accessible and compassionate healthcare, recognizing the growing demand for mental health resources and the persistent inequities in women's health. By offering trusted and holistic care, Caraway empowers college students to effectively manage their health in a complex and often challenging healthcare landscape.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Britto's Brainwaves is a healthcare company that emerges as a beacon for those seeking in-depth medical insights.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Sesame, Inc., operating as SesameCare, is a healthcare technology company founded in 2018 and based in New York, New York. The company has developed an innovative platform that enables users to book medical appointments and access healthcare services conveniently and affordably. By leveraging an AI-enabled marketplace, SesameCare eliminates the need for health insurance, fostering competition among healthcare providers based on quality, accessibility, and pricing. This approach allows the company to offer Americans high-quality medical care at significantly reduced costs. Additionally, Sesame is recognized as the official telehealth partner of Costco, further enhancing its reach and service offerings.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Waltz Health is a company focused on innovating the pharmaceutical supply chain by developing technology-driven solutions for pricing, distribution, and prescription of medications. It collaborates with various partners, including consumers, payers, and pharmacies, to create smarter ways to manage prescription care. The company utilizes AI-driven marketplaces to reduce costs and offers consumer tools that enhance decision-making regarding healthcare. These tools provide users with better pricing, comprehensive information, and resources aimed at lowering expenses, empowering consumers, and enabling payers to effectively manage their pharmacy benefits. Through these efforts, Waltz Health strives to improve the overall experience and affordability of prescription medications.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

SpunOut is an Irish non-governmental organization that provides online youth information. It also provides youth information and supportive factsheets on topics such as mental health, politics, physical health, education, and employment.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Patina Health operates a specialized primary care model focused on improving healthcare outcomes for older adults. Their approach prioritizes personalization, accessibility, and family involvement, aiming to enhance the aging experience by addressing the unique needs of this demographic.

Modern Age is a health and wellness platform focused on simplifying the aging process for individuals. The company develops health monitoring software that utilizes computer vision and machine learning to assess skin, hair, and bone health. By collecting data from smart devices, Modern Age creates a comprehensive digital profile of an individual's health and daily activities. This information enables the platform to provide personalized recommendations and treatments, empowering users to manage their well-being more effectively and adopt healthier lifestyles as they age.

Sprinter Health is a mobile healthcare company that provides on-demand services by sending full-time nurses and phlebotomists to patients' homes. The company aims to improve access to preventive care through modern house calls, enhancing the patient experience and satisfaction. By utilizing a cost-effective hybrid care model, Sprinter Health connects patients with essential healthcare services, allowing them to receive quality care in the comfort of their own homes. This approach not only improves health outcomes but also addresses the growing demand for convenient and accessible healthcare solutions.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Locanabio, Inc., based in San Diego, California, is a biotechnology company specializing in RNA-targeted gene therapies. Founded in 2016, the company focuses on developing treatments for severe neurodegenerative, neuromuscular, and retinal diseases. Locanabio's platform is designed to modify disease-causing RNA, offering therapeutic candidates distinct from traditional DNA-targeted approaches. The company aims to address a spectrum of underserved diseases, including those affecting the nervous system, muscles, and eyes.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

CareBridge Health is a technology and service provider based in Nashville, Tennessee, dedicated to improving the lives of individuals with physical, intellectual, or developmental disabilities who require long-term support services. Founded in 2009, the company offers a range of services, including electronic visit verification, data aggregation, and 24/7 clinical support for patients, their families, and paid caregivers. CareBridge specifically serves individuals who are on Medicaid or who are dually eligible for Medicare and Medicaid, ensuring that they receive essential services and equipment needed to maintain their independence at home. By facilitating continuous communication between care teams and caregivers, CareBridge aims to enhance the quality of care and support available to its members.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Locanabio, Inc., based in San Diego, California, is a biotechnology company specializing in RNA-targeted gene therapies. Founded in 2016, the company focuses on developing treatments for severe neurodegenerative, neuromuscular, and retinal diseases. Locanabio's platform is designed to modify disease-causing RNA, offering therapeutic candidates distinct from traditional DNA-targeted approaches. The company aims to address a spectrum of underserved diseases, including those affecting the nervous system, muscles, and eyes.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Senosis Health is a startup focused on mobile health monitoring. The company develops applications that utilize the capabilities of smartphones, such as the accelerometer, microphone, flash, and camera, to measure, diagnose, and manage diseases. Their solutions include monitoring lung health and hemoglobin counts, providing users with accessible healthcare tools directly on their mobile devices.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

CareMessage is a technology non-profit focused on enhancing patient engagement among low-income populations in the United States. The organization operates the largest patient engagement platform, powered by its Health Equity Engine™, which integrates messaging, data, and interoperability to facilitate access to care and improve clinical outcomes. Since its inception in 2013, CareMessage has reached 20 million patients, distinguishing itself as a proven solution for advancing health equity at scale. The platform provides essential reminders, information, and education regarding primary care appointments, preventive screenings, and disease self-management. By serving community health centers, health plans, and free clinics, CareMessage empowers patients to take charge of their health while reinvesting its revenue into impactful initiatives, driven by a team that includes individuals with lived experiences in these communities.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.

ZappRx is a digital health company based in Boston, Massachusetts, founded in 2012. It specializes in providing a cloud-based platform that streamlines the process of ordering specialty medications for healthcare providers, specialty pharmacies, and biopharma companies. The platform facilitates secure digital interactions among providers, pharmacists, and payers, reducing reliance on traditional methods like faxes and phone calls. By automating prescription management and prior authorization processes, ZappRx enhances efficiency in collecting and maintaining necessary information for specialty prescribing. This includes details such as pharmacy information, payer requirements, and clinical history. The company's platform is utilized across various medical fields, including pulmonary, cardiology, and gastroenterology.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Spruce Health, Inc. is a healthcare technology company based in San Francisco, California, established in 2013. It offers an interactive mobile application that facilitates communication between patients and dermatologists for the diagnosis and treatment of various skin conditions, including acne, eczema, psoriasis, and male hair loss. The company aims to improve the healthcare experience by reducing wait times and simplifying the process of accessing medical care. Spruce Health is dedicated to enhancing the patient-physician relationship and ensuring quality healthcare is accessible at any time and from any location. Through its platform, Spruce Health seeks to provide affordable healthcare solutions and increase patient satisfaction while improving practice efficiency for healthcare providers.

CareMessage is a technology non-profit focused on enhancing patient engagement among low-income populations in the United States. The organization operates the largest patient engagement platform, powered by its Health Equity Engine™, which integrates messaging, data, and interoperability to facilitate access to care and improve clinical outcomes. Since its inception in 2013, CareMessage has reached 20 million patients, distinguishing itself as a proven solution for advancing health equity at scale. The platform provides essential reminders, information, and education regarding primary care appointments, preventive screenings, and disease self-management. By serving community health centers, health plans, and free clinics, CareMessage empowers patients to take charge of their health while reinvesting its revenue into impactful initiatives, driven by a team that includes individuals with lived experiences in these communities.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Navigenics, Inc. specializes in personalized genetics testing and health counseling services aimed at educating individuals and their physicians about genetic predispositions. The company provides genetic information and analysis to empower clients to take proactive measures to prevent disease, facilitate early diagnosis, and effectively manage health conditions. Navigenics delivers its services through a network of medical centers and physicians, as well as employer wellness programs at leading corporations. By motivating individuals to act on their genetic insights, Navigenics seeks to enhance overall health outcomes and reduce the impact of potential diseases.

Sprinter Health is a mobile healthcare company that provides on-demand services by sending full-time nurses and phlebotomists to patients' homes. The company aims to improve access to preventive care through modern house calls, enhancing the patient experience and satisfaction. By utilizing a cost-effective hybrid care model, Sprinter Health connects patients with essential healthcare services, allowing them to receive quality care in the comfort of their own homes. This approach not only improves health outcomes but also addresses the growing demand for convenient and accessible healthcare solutions.